Dynavax Technologies Corporation reaffirmed financial guidance for the full year 2024. For the year, the company expects HEPLISAV-B net product revenue between approximately $265 million - $280 million, including approximately $3 million in ex-U.S. sales through commercialization partnership in Germany.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.39 USD | -3.88% | +2.52% | -18.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.53% | 1.49B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- DVAX Stock
- News Dynavax Technologies Corporation
- Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024